The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of PSMA-extracellular vesicles in oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy: A multi-center observational study.
 
Fabrice Lucien
No Relationships to Disclose
 
Jack R. Andrews
No Relationships to Disclose
 
Yohan J Kim
No Relationships to Disclose
 
Edlira Horjeti
No Relationships to Disclose
 
Ali Arafa
No Relationships to Disclose
 
Philip Sutera
Stock and Other Ownership Interests - Merck; Pfizer
 
Aurélie De Bruycker
No Relationships to Disclose
 
Carole Mercier
No Relationships to Disclose
 
Ryan Phillips
No Relationships to Disclose
 
Daniel Song
Stock and Other Ownership Interests - Pfizer
Honoraria - Lantheus Medical Imaging
Consulting or Advisory Role - BioProtect; Isoray
Research Funding - BioProtect; Candel Therapeutics
Travel, Accommodations, Expenses - Lantheus Medical Imaging
 
Ana Ponce Kiess
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd.
Travel, Accommodations, Expenses - Novartis
(OPTIONAL) Uncompensated Relationships - Novartis; POINT Biopharma
 
Piet Ost
Consulting or Advisory Role - Astellas Pharma; Bayer; Curium Pharma; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Ferring; Janssen
 
Phuoc T. Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Dendreon; GenomeDx; Janssen; Lantheus Medical Imaging; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical
 
Daniel S Childs
Employment - Mayo Clinic
Honoraria - International Centers for Precision Oncology Foundation; IntrinsiQ; MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Janssen Biotech (Inst); Novartis (Inst)
Research Funding - Janssen Biotech (Inst)
Travel, Accommodations, Expenses - Prostate Cancer Foundation
 
A. Oliver Sartor
Stock and Other Ownership Interests - Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Fusion Pharmaceuticals; Lilly; POINT Biopharma; PSMA Therapeutics; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Lantheus Medical Imaging
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Clarity Pharmaceuticals; Clovis Oncology; Constellation Pharmaceuticals; Dendreon; EMD Serono; Fusion Pharmaceuticals; Hengrui Therapeutics; Isotopen Technologien; Janssen; MacroGenics; Medscape; Merck; Morphimmune; Myovant Sciences; Myriad Genetics; Noria Therapeutics; Northstar; Novartis; Noxopharm; Pfizer; Point Biopharma; Progenics; Ratio; Sanofi; Telix Pharmaceuticals; TEmpus; TeneoBio; Tessa Therapeutics; Theragnostics
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Endocyte (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Progenics; Sanofi (Inst); SOTIO
Patents, Royalties, Other Intellectual Property - Koochekpour, Sartor AO, inventors. Saposin C and receptors as targets for treatment of benign and malignant disorders. US patent awarded January 23, 2007 (patent no. 7,166,691).
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Lantheus Medical Imaging; Progenics; Sanofi
 
Jacob Orme
Consulting or Advisory Role - NaNotics
Patents, Royalties, Other Intellectual Property - Patents regarding PD-L1 cleavage and immunotherapy resistance in multiple cancers. (Inst)
 
Sean Sunghun Park
Honoraria - NaNotics
Consulting or Advisory Role - Nanotics
Research Funding - Nanotics